AUT and Zeacann announce new research partnership
Auckland University of Technology has partnered with Zeacann Ltd to research the development of medicinal cannabis products in New Zealand.
Read more at https://drugdelivery.aut.ac.nz/research
2 June 2018: AUT and PharmaCann collaborate
1 June 2018: AUT News: Auckland University of Technology has partnered with PharmaCann New Zealand Ltd
28 June 2018: NZ Herald: AUT signs deal with Zeacann to develop locally-made, cheaper medical cannabis
28 June 2018: NZ Doctor: AUT and PharmaCann to research medicinal cannabis for clinical trials in New Zealand
11 May 2020: AUT and Zeacann green light medicinal cannabis
8 June 2020: NZ Herald: AUT to offer medicinal cannabis paper
18 May 2020: AUT offers medicinal cannabis paper
10 June 2020: AUT partners with Zeacann to present Medicinal Cannabis Science paper
31 July 2020: NZ Herald: Health professionals tune in, turn on to AUT medicinal cannabis paper - sending numbers through roof
11 August 2020: Zeacann secures first cultivation licence issued under New Zealand's Medicinal Cannabis Scheme
14 October 2020: First paper published by AUT and Zeacann's cannabis research team
10 June 2021: Second round of AUT postgraduate Medicinal Cannabis Science paper utilises Zeacann expertise
AUT and PharmaCann collaborate
02 Jul, 2018
AUT has partnered with PharmaCann New Zealand Ltd to research the development of medicinal cannabis products in New Zealand. AUT Dean of Health and Environmental Sciences Max Abbott and PharmaCann CEO Chris Fowlie have signed an agreement outlining collaboration between AUT’s Drug Delivery Research Group (DDRG) and Auckland-based PharmaCann.
“It is important to increase scientific understanding of the ways in which cannabis and cannabis derivatives can benefit health. It is also important that these products are of known and reliable quality and are affordable,” says Professor Abbott.
“PharmaCann intends to develop innovative cannabis-based products for therapeutic use by New Zealand patients and to serve global markets,” says PharmaCann CEO Chris Fowlie. “Our partnership with AUT will help accelerate product development and ensure products are rigorously assessed and made to the highest standards.”
The parties aim to have therapeutic formulations developed and in clinical trials by the time new government regulations for cultivation and manufacture of medicinal cannabis-based products (CBPs) in New Zealand come into force, probably next year.
Although New Zealand doctors can now prescribe the medical product cannabidiol (CBD), it can only be sourced from overseas and is not eligible for Pharmac funding, making it prohibitively expensive and out of reach of most New Zealanders.
“Our vision is to develop and manufacture in New Zealand natural cannabis-based products that are as good as anything available overseas, at more affordable prices for patients,” says Fowlie.
AUT’s Drug Delivery Research Group will work on extraction of medicinal compounds from locally grown plants and the development of oral and topical (skin) formulation.
AUT DDRG News
01 June 2018
Auckland University of Technology has partnered with PharmaCann New Zealand Ltd to research the development of medicinal cannabis products in New Zealand.
AUT Dean of Health and Environmental Sciences Max Abbott and PharmaCann CEO Chris Fowlie have signed an agreement outlining collaboration between AUT’s Drug Delivery Research Group and the Auckland-based PharmaCann.
“It is important to increase scientific understanding of the ways in which cannabis and cannabis derivatives can benefit health. It is also important that these products are of known and reliable quality and are affordable,” says Professor Abbott.
“PharmaCann intends to develop innovative cannabis-based products for therapeutic use by New Zealand patients and to serve global markets,” says PharmaCann CEO Chris Fowlie. “Our partnership with AUT will help accelerate product development and ensure products are rigorously assessed and made to the highest standards.”
The parties aim to have therapeutic formulations developed and in clinical trials by the time new government regulations for cultivation and manufacture of medicinal cannabis-based products (CBPs) in New Zealand come into force, probably next year.
Although New Zealand doctors can now prescribe the medical product cannabidiol (CBD), it can only be sourced from overseas and is not eligible for Pharmac funding, making it prohibitively expensive and out of reach of most New Zealanders.
“Our vision is to develop and manufacture in New Zealand natural cannabis-based products that are as good as anything available overseas, at more affordable prices for patients,” says Fowlie.
AUT’s Drug Delivery Research Group, led by Dr Ali Seyfoddin, will work on extraction of medicinal compounds from locally grown plants and the development of oral and topical (skin) formulations.
Notes AUT’s Drug Delivery Research Group conducts research to safely and efficiently deliver drugs to their site of action. The DDRG works with 3D printed, nano and microcapsule-based drug delivery systems for human and veterinary use.
PharmaCann New Zealand Ltd is a vertically integrated cannabis business established to provide safe access to legitimate medicinal cannabis at more affordable prices. The company intends to develop and build cultivation and production facilities in New Zealand to produce a range of CBPs including extractions and formulations with a variety of delivery methods.